J Clin Endocrinol Metab (2010) 95:2497502.10.1210/jc.2009-2247 48 LuqueRMIbez-CostaANetoLVTaboadaGFHormaechea-AgullaDKasukiLet alTruncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas
New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound
Your Program Includes: A comprehensive telehealth consultation Personalized recommendation based on your goals and symptoms Review of current medications, supplements, and medical conditions Guidance on appropriate injection option, if clinically appropriate Coordination through a licensed pharmacy & convenient home delivery of medicine Ongoing support and follow-up as needed Is This Right for You
(2008) published that selenite (Se) treatment decreased general DNA methylation and caused partial promoter demethylation and re-expression of the TSGs adenomatous polyposis coli (APC) and cellular stress response 1, a gene involving tumor growth and metastasis
Jain, F
The glycemic improvements were also substantial, with significant reductions in A1c across all dose groups
